Filing Flows › Pfizer (PFE) › Capital expenditures
Pfizer (PFE) capital expenditures by quarter
Pfizer's capital expenditures were $573M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 6 quarters it ranged from $436M (Q1 2026) to $845M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $573M | +8% | -5% |
| Q2 2026 | $533M | +22% | — |
| Q1 2026 | $436M | -48% | -23% |
| Q4 2025 | $845M | +40% | — |
| Q3 2025 | $602M | +7% | — |
| Q1 2025 | $564M | — | — |
Q3 2026 at a glance
Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%, net earnings $3.3B, operating cash flow $5.4B. The chart follows the revenue to costs, profit and cash.
Questions
What is Pfizer's capital expenditures?
Pfizer's capital expenditures were $573M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Pfizer's capital expenditures changed?
Over the last 6 quarters it ranged from $436M (Q1 2026) to $845M (Q4 2025).